Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT)

By afschroeder • July 23, 2026

Skoulidis F, Jabbour SK, Garon EB, Iyengar P, Scagliotti G, Ferrer L, Etchepare G, Gallinato O, Faure J, Bernard P, Colin T, Menu P, Lin Y, Cai L, Chaudhry AA, Remorino A, Stewart R, Luciani-Silverman L, Miller K, Dellamonica D, Faria J, Zhang Y. Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT). Clin Cancer Res. 2026 Jul 22. doi: 10.1158/1078-0432.CCR-25-3729. Epub ahead of print. PMID: 42485106.

Tags: Hematology/Oncology, Publications

L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 GlutaPanc trial

Gong J, Muranaka H, Choi SY, Tighiouart M, Bhute S, Aja ER, Jacobs JP, Stotland A, Van Eyk J, Elmadbouh OHM, Edderkaoui M, Tanaka S,[...]

Unmasking Factor XIII Deficiency: Recurrent Intracranial Hemorrhage Despite Normal Coagulation Studies

Ramesh K, Hui G, Shodiya M, Palaskas NJ. Unmasking Factor XIII Deficiency: Recurrent Intracranial Hemorrhage Despite Normal Coagulation Studies. Cureus. 2026 Jul 29;18(7):e113621. doi: 10.7759/cureus.113621.[...]

Urgent Chemotherapy for Aggressive Metastatic Neuroendocrine Cancer With Impending Hepatic Failure: A Case Report

Rashba GB, Kaplan L, Bolos D, Baltayan A, Backer S. Urgent Chemotherapy for Aggressive Metastatic Neuroendocrine Cancer With Impending Hepatic Failure: A Case Report. Cureus.[...]